Anzeige
Mehr »
Mittwoch, 08.10.2025 - Börsentäglich über 12.000 News
Defence-Aktie mit Ritterschlag: Regierungs-Einladung zur größten Militärmesse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D38R | ISIN: US0547548588 | Ticker-Symbol: AY20
Lang & Schwarz
08.10.25 | 07:00
1,570 Euro
-100,00 % -1,570
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AYTU BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
AYTU BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,5301,61007:00

Aktuelle News zur AYTU BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.09.Aytu BioPharma: Strategische Neuausrichtung mit Fokus auf Wachstum und neues Antidepressivum Exua9
24.09.Aytu BioPharma, Inc.: Aytu BioPharma to Present at Upcoming September 2025 Conferences267DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central...
► Artikel lesen
24.09.Aytu outlines EXXUA launch targeting $22B MDD market while streamlining ADHD portfolio2
23.09.Earnings Call zu Q4 2025: Aytu BioPharma meldet Umsatzwachstum und strategische Weichenstellungen1
23.09.Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA326Full year fiscal 2025 net revenue of $66.4 millionFull year fiscal 2025 net loss of $13.6 millionFull year fiscal 2025 adjusted EBITDA1 of $9.2 million$31.0 million cash balance at June 30, 2025Exclusive...
► Artikel lesen
AYTU BIOPHARMA Aktie jetzt für 0€ handeln
23.09.Aytu BioPharma GAAP EPS of -$2.93 misses by $2.88, revenue of $15.1M misses by $2.82M3
23.09.AYTU BIOPHARMA, INC - S-8, Securities to be offered to employees in employee benefit plans5
23.09.AYTU BIOPHARMA, INC - 10-K, Annual Report3
23.09.AYTU BIOPHARMA, INC - 8-K, Current Report2
22.09.Aytu BioPharma FQ4 2025 Earnings Preview5
22.09.Earnings Outlook For Aytu BioPharma1
16.09.Aytu BioPharma, Inc.: Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025291DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central...
► Artikel lesen
01.07.Lake Street initiates coverage on Aytu Biosciences stock with Buy rating15
25.06.Aytu BioPharma, Inc.: Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA242DENVER, CO / ACCESS Newswire / June 25, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous...
► Artikel lesen
23.06.Aytu BioPharma verlängert Kreditvereinbarung vor Markteinführung eines Antidepressivums2
23.06.Aytu BioPharma extends loan agreement ahead of depression drug launch2
23.06.Aytu BioPharma, Inc.: Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA288Term loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 million currentlyExpanded revolving line of credit facility by $1.5 millionExpanded...
► Artikel lesen
17.06.AYTU BIOPHARMA, INC - 8-K, Current Report1
09.06.Aytu BioPharma, Inc.: Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA Opportunity and Commercialization Plan427Gross proceeds from offering total $16.6 million.Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine...
► Artikel lesen
09.06.Aytu BioPharma to commercialise Exxua for MDD in the US6
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1